Study summary

Phase IIIb, Open-label, randomized, controlled multi-centre study. Induction therapy phase for 6 months where all subjects receive 2 ELIGARD depot injections. Those subjects with hormone responsive prostate cancer will be randomized and will receive either intermittent or continuous ELIGARD treatment for 36 months. Following this treatment period, subjects will enter a long-term follow-up period for 48 months.

Additional Study Details

Phase
Phase 3
Product
  • leuprorelin acetate
  • Type
    Interventional
    Masking
    None (Open Label)
    Enrollment number
    706
    Show Additional Study Details

    Study documents

    Scientific Results Summary
    Available Language(s): English
    Plain Language Summary
    Available Language(s): English

    Get more information

    Would you like more information about clinical trial sites that are recruiting participants for A phase IIIb study of intermittent versus continuous hormone deprivation treatment with ELIGARD? Contact us by filling out your information to the right and we’ll respond to you.

    • A patient
    • A caregiver
    • A parent
    • A healthcare provider
    • A patient advocate
    • Algeria
    • Argentina
    • Armenia
    • Australia
    • Austria
    • Belarus
    • Belgium
    • Bosnia And Herzegovina
    • Brazil
    • Bulgaria
    • Canada
    • Chile
    • China
    • Colombia
    • Croatia
    • Czech Republic
    • Denmark
    • Dominican Republic
    • Egypt
    • Estonia
    • Finland
    • Former Serbia and Montenegro
    • France
    • Georgia
    • Germany
    • Greece
    • Guatemala
    • Hong Kong
    • Hungary
    • Iceland
    • India
    • Indonesia
    • Ireland
    • Israel
    • Italy
    • Japan
    • Jordan
    • Kazakhstan
    • Latvia
    • Lebanon
    • Lithuania
    • Macedonia
    • Malaysia
    • Mexico
    • Montenegro
    • Morocco
    • Netherlands
    • New Zealand
    • Norway
    • Panama
    • Peru
    • Philippines
    • Poland
    • Portugal
    • Puerto Rico
    • Republic of Korea
    • Republic of Moldova
    • Romania
    • Russian Federation
    • Saudi Arabia
    • Serbia
    • Singapore
    • Slovakia
    • Slovenia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Taiwan, Province of China
    • Thailand
    • Turkey
    • Ukraine
    • United Kingdom
    • United States
    • Vietnam

    By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

      Locations

      Contact Us
      Contact Us
      Completed
      Bruxelles, Belgium, 1200
      Completed
      Liege, Belgium, 4000
      Completed
      Brussel, Belgium
      Completed
      Bruxelles, Belgium, 1070
      Completed
      Leuven, Belgium, B-3000
      Completed
      Bmo, Czech Republic, 65691
      Completed
      Jablonec nad Nisou, Czech Republic, 46660
      Completed
      Olomouc, Czech Republic, 7521
      Completed
      Usti nad Labem, Czech Republic, 40113
      Completed
      Tampere, Finland, FIN-33521
      Completed
      Joensuu, Finland, FIN-80210
      Completed
      Paris, France, 75007
      Completed
      Toulon, France, 83000
      Completed
      Bordeaux, France, 33073
      Completed
      Paris, France, 94275
      Completed
      Caen-Cedex, France, 14033
      Completed
      Suresnes, France, 92151
      Completed
      Nantes, France, 44093
      Completed
      Cergy-Pontoise, France, 95301
      Completed
      Avignon, France, 84000
      Completed
      Ploemeur, France, 53275
      Completed
      Brest, France, 29609
      Completed
      Pierre-Benite, France, 69310
      Completed
      Rouen, France, 76031
      Completed
      Paris, France, 75014
      Completed
      Grenoble, France, 38043
      Completed
      Marseille, France, 13915
      Completed
      Toulouse, France, 31054
      Completed
      Hagenow, Germany, 19230
      Completed
      Neustadt i. Sachsen, Germany, 01844
      Completed
      Dresden, Germany, 01324
      Completed
      Bautzen, Germany, 02625
      Completed
      Trier, Germany, 54290
      Completed
      Bad Neuenaher, Germany, 53474
      Completed
      Hettstedt, Germany, 06333
      Completed
      Halle/Saale, Germany, 06132
      Completed
      Leipzig, Germany, 04105
      Completed
      Dresden, Germany, 01307
      Completed
      Szolnok, Hungary, 5000
      Completed
      Veszprem, Hungary, 8200
      Completed
      Nyiregyhaza, Hungary, 4400
      Completed
      Budapest, Hungary, 1106
      Completed
      Tatabanya, Hungary, 2800
      Completed
      Kaposvar, Hungary, 7400
      Completed
      Roma, Roma, Italy, 00189
      Completed
      Desio, Milano, Italy, 20033
      Completed
      Bergamo, Bergamo, Italy, 24128
      Completed
      Parma, Parma, Italy, 43100
      Completed
      Bologna, Bologna, Italy, 40138
      Completed
      Martin, Slovakia, 03659
      Completed
      Skalica, Slovakia, 90982
      Completed
      Trencin, Slovakia, 91101
      Completed
      Barcelona, Spain, 8003
      Completed
      Valencia, Spain, 46009
      Completed
      Barcelona, Spain, 8035
      Completed
      Madrid, Spain, 28041
      Completed
      Alcorcon, Madrid, Spain, 28922
      Completed
      St. Petersburg, Russian Federation, 198255
      Completed
      Moscow, Russian Federation, 125101
      Completed
      Moscow, Russian Federation, 115478
      Completed
      St. Petersburg, Russian Federation, 198013
      Completed
      Moscow, Russian Federation, 125284
      Completed
      Milano, Italy
      Completed
      Bari, Italy
      Completed
      Ancona, Italy
      Completed
      Messina, Italy
      Completed
      Chieti, Italy
      Completed
      Granada, Spain
      Completed
      Madrid, Spain
      Completed
      La Coruna, Spain

      Frequently Asked Questions

      Are clinical trials only for people with advanced cancer?

      While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

      Will I have to stop my current treatment to participate in a clinical trial?

      Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

      Should I be worried about getting a placebo?

      In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

      Do I need a referral from my doctor to take part in a study?

      Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

      Explore More

      1

      What are clinical trials?

      2

      Why are Clinical Trials Important?

      3

      Why Participate in a Clinical Trial?